SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-282424
Filing Date
2023-11-24
Accepted
2023-11-22 20:45:06
Documents
13
Period of Report
2023-11-21
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d23731d8k.htm   iXBRL 8-K 41166
2 EX-3.1 d23731dex31.htm EX-3.1 6053
  Complete submission text file 0001193125-23-282424.txt   179734

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA agle-20231121.xsd EX-101.SCH 2845
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE agle-20231121_lab.xml EX-101.LAB 19503
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE agle-20231121_pre.xml EX-101.PRE 12153
7 EXTRACTED XBRL INSTANCE DOCUMENT d23731d8k_htm.xml XML 3737
Mailing Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453 6176515940
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 231434870
SIC: 2834 Pharmaceutical Preparations